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ABSTRACT
Epigenetic or transcriptional silencing of important tumor suppressors has been 
described to contribute to cell survival and tumorigenesis in chronic lymphocytic 
leukemia (CLL). Using gene expression microarray analysis, we found that thousands 
of genes are repressed more than 2-fold in CLL compared to normal B cells; however 
therapeutic approaches to reverse this have been limited in CLL. Following treatment 
with the Hsp90 inhibitor 17-DMAG, a significant number of these repressed genes 
were significantly re-expressed. One of the genes significantly repressed in CLL and 
up-regulated by 17-DMAG was suppressor of cytokine signaling 3, (SOCS3). SOCS3 
has been shown to be silenced in solid tumors as well as myeloid leukemia; however 
little is known about the regulation in CLL. We found that 17-DMAG induces expression 
of SOCS3 by via the activation of p38 signaling, and subsequently inhibits AKT and 
STAT3 phosphorylation resulting in downstream effects on cell migration and survival. 
We therefore suggest that SOCS3 is an important signaling protein in CLL, and Hsp90 
inhibitors represent a novel approach to target transcriptional repression in B cell 
lymphoproliferative disorders which exhibit a substantial degree of gene repression.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a disease of 
mature B-cells that accumulate over time due in large part 
to a resistance to apoptosis. Due to the slowly progressing 
nature of this disease, studies to determine the molecular 
events leading to this defective apoptosis are challenging. 
Our group has previously reported that as disease 
develops in a CLL mouse model, genes become silenced 
in a progressive manner [1]. Even though a high degree of 
methylation is observed in both this mouse model and in 
CLL patient samples, agents targeting methylation such 
as decitabine have proven ineffective in CLL therapy [2]. 
Therefore, other novel methods to reverse gene silencing 
in CLL are an attractive therapeutic option.
We also observed in the CLL mouse model early 
transcriptional mechanisms of gene repression involving 
NF-κB [1]. NF-κB is a family of transcription factors 
which has been shown to be constitutively active in 
CLL, typically leading to the transcriptional activation 
of cell survival and proliferation genes which contribute 
to disease progression as well as therapeutic resistance 
[3, 4]. However several studies have also demonstrated 
that NF-κB plays a prominent role in gene repression as 
well, either through recruitment of co-repressors [5–7] or 
through epigenetic silencing [8]. These studies suggest 
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that the inhibition of NF-κB has the potential to increase 
specific gene targets.
Our lab has previously described the Hsp90 
inhibitor 17-DMAG, which is a potent inhibitor of NF-
κB signaling in CLL [9]. Hsp90 regulates the stability of 
proteins involved in multiple signaling pathways that are 
directly related to CLL cell survival, and we as well as 
others have previously established Hsp90 inhibition as 
a promising therapeutic option in CLL [9–13]. Despite 
this promising preclinical data, Hsp90 inhibitors to date 
in other cancers have had limited clinical efficacy, in part 
due to unfavorable side effects associated with treatment. 
A better understanding of the mechanism should help to 
refine treatment strategies using Hsp90 inhibitors both as 
monotherapy and also in combination with other agents. 
Our earlier work was primarily focused on genes which 
are activated by NF-κB and subsequently inhibited 
by 17-DMAG treatment, and did not address the role 
of 17-DMAG in reversing gene repression. Therefore 
in the current study we focus on 17-DMAG mediated 
transcriptional induction or re-expression, and identify 
suppressor of cytokine signaling 3 (SOCS3). The role 
of SOCS3 has not been characterized in CLL; however, 
epigenetic inactivation of SOCS3 has been described to 
lead to enhanced signaling of survival pathways in solid 
tumors as well as acute myeloid leukemia (AML)[14–17]. 
SOCS3 is a negative regulator of the JAK/STAT signaling 
pathway induced by IL-6, and it’s loss could contribute 
to cell signaling induced by cytokine production from 
the CLL microenvironment. Therefore re-expression 
of SOCS3 following treatment with 17-DMAG could 
represent an important aspect of the cytotoxic mechanism 
of Hsp90 inhibitors.
RESULTS
Gene expression profiling in CLL with 17-
DMAG reveals SOCS3 as a repressed target
In this study, we analyzed gene expression in CLL 
patient samples following treatment with the Hsp90 
inhibitor 17-DMAG. We performed expression profiling 
using the Affymetrix U133 plus 2 array in CLL patient 
samples (2 pools, each consisting of 5 samples) treated 
with either vehicle control or 1uM 17-DMAG for 24 
hours. We also analyzed expression in B cells isolated 
from normal donors (1 pool consisting of 6 samples) 
compared to the CLL samples. We identified 798 probes 
up-regulated more than 4-fold in CLL samples compared 
to normal B cells (Supplemental Table 1), while 467 
probes were repressed more than 2-fold in CLL samples 
(Supplemental Table 2). In the current study we have 
focused on the genes that are repressed in CLL, and in 
particular how these genes can be therapeutically targeted 
for re-expression.
Following treatment with 17-DMAG, a total of 189 
probes were decreased more than 4-fold (Supplemental 
Table 3). Interestingly, although 17-DMAG is known to 
inhibit multiple transcriptional activators, there were many 
probes (87) which increased more than 4-fold following 
treatment (Supplemental Table 4), indicating a potential 
effect on a transcriptional repressor. Using Ingenuity 
pathway analysis, we investigated the pathways that 
are deregulated in CLL cells, both compared to normal 
B cells as well as following treatment with 17-DMAG. 
Overall, 345 canonical pathways were deregulated in CLL 
cells compared to normal B cells and 172 were affected 
by 17-DMAG treatment. SOCS3 is a critical member 
of 25 pathways altered in CLL B cells (Table 1), and 
22 pathways altered by 17-DMAG treatment (Table 2), 
and these pathways predominantly involve cytokine 
signaling. Due to the predominance of SOCS3 in 17-
DMAG regulated pathways, and the important role of this 
gene in cell growth and survival signaling we decided to 
further explore the mechanism of SOCS3 regulation. We 
first validated the microarray results using real time RT-
PCR and verified that SOCS3 is significantly repressed in 
CLL compared to normal B cells (Figure 1A, displayed 
as SOCS3 fold change relative to the CLL average, p < 
0.001). Furthermore, in vitro treatment with 17-DMAG 
increased SOCS3 as early as 8 hours (p <0.001) and 
peaking at 16 hours (p <0.001; Figure 1B). The induction 
by 24 hours while still significant, is more modest as cells 
start to undergo apoptosis at this point. Importantly, while 
17-DMAG also increased SOCS3 expression in normal 
B cells at 24 hours, the degree of up-regulation was 
significantly less than that observed in CLL B cells (Figure 
1B, p = 0.015). This is consistent with reduced killing 
in these cells (compared to CLL B cells) as previously 
demonstrated by our group [9]. Finally, we found that 
there was a significant correlation between SOCS3 up-
regulation and cell death following 17-DMAG treatment. 
The samples that had a larger change in viability in the 
17-DMAG treated condition relative to the vehicle treated 
(indicating more cell death) also had higher induction 
of SOCS3 (Figure 1C; Pearson r = 0.64, p = 0.001). We 
did not observe an up-regulation of SOCS3 in the B cell 
leukemia cell lines investigated (697, Mec1) with the 
exception of the OSU-CLL cell line (derived from CLL 
patient B cells) recently described by our group [18] 
(Supplemental Figure 1), indicating that this mechanism 
may be specific to the primary CLL B cells.
Despite the consistent increase in SOCS3 transcript, 
we were not able to detect a corresponding increase in 
protein level following 17-DMAG treatment. This is in 
large part due to the non-specific nature of the SOCS3 
antibodies. We tested three different commercially 
available antibodies for SOCS3, and all three detected a 
25 kD band (the predicted size of SOCS3 protein), even 
in cell lines with undetectable transcript levels of SOCS3 
Oncotarget28686www.impactjournals.com/oncotarget
Table 1: Ingenuity canonical pathways involving SOCS3: CLL vs NB
# Ingenuity Canonical Pathways 
Involving SOCS3: CLL vs NB
Molecules
1 JAK/Stat Signaling STAT4,SOCS1,SOCS3,FOS,JUN,CDKN1A,SOS1,AKT3,JAK2,NFKB2,
IL6,NFKB1
2 Type I Diabetes Mellitus Signaling MAP2K6,SOCS3,SOCS1,NFKBIA,HLA-DRB1,CD80,IFNGR1,HSPD1,
NFKB2,JAK2,NFKB1,IRF1,BCL2
3 Erythropoietin Signaling SOCS1,SOCS3,FOS,JUN,NFKBIA,SOS1,AKT3,JAK2,NFKB2,NFKB1
4 IL-6 Signaling MAP2K6,FOS,SOCS3,ABCB1,SOCS1,CXCL8,JUN,NFKBIA,SOS1, 
AKT3,NFKB2,JAK2,IL6,NFKB1
5 IL-10 Signaling MAP2K6,FCGR2C,SOCS3,FOS,JUN,NFKBIA,NFKB2,IL6,FCGR2B, 
NFKB1
6 3-phosphoinositide Degradation SOCS3,DUSP8,FIG4,STYXL1,PTPN12,DUSP2,MTMR6,CDC25B, 
INPP5F,TMEM55A,PTPRJ,DUSP1,DUSP10,PTPN22
7 STAT3 Pathway MYC,SOCS1,SOCS3,BMPR1A,TGFBR3,CDKN1A,BMPR2,JAK2, 
BCL2












11 Role of JAK2 in Hormone-like  
Cytokine Signaling
SOCS1,SOCS3,IRS2,JAK2,HLTF
12 Prolactin Signaling MYC,SOCS1,SOCS3,FOS,JUN,SOS1,JAK2,IRF1
13 Role of JAK1 and JAK3 in γc  
Cytokine Signaling
BLNK,SOCS1,SOCS3,SYK,IL21R,IRS2,JAK2
14 Role of JAK family kinases in  
IL-6-type Cytokine Signaling
SOCS1,SOCS3,JAK2,IL6
15 Acute Phase Response Signaling MAP2K6,FOS,SOCS3,SOCS1,TCF4,JUN,NFKBIA,SOS1,SERPINF1, 
AKT3,NFKB2,JAK2,IL6,NFKB1




17 Role of Macrophages, Fibroblasts 





18 3-phosphoinositide Biosynthesis MTMR6,CDC25B,SOCS3,DUSP8,PTPRJ,DUSP1,DUSP10,FIG4, 
STYXL1,PTPN12,PTPN22,DUSP2
19 IL-9 Signaling SOCS3,IRS2,NFKB2,NFKB1
20 IGF-1 Signaling SOCS1,SOCS3,FOS,JUN,SOS1,AKT3,IRS2,JAK2
21 Type II Diabetes Mellitus Signaling SOCS1,SOCS3,NFKBIA,AKT3,IRS2,NFKB2,NFKB1,ACSL1
22 Growth Hormone Signaling SOCS1,SOCS3,FOS,JAK2,RPS6KA2
23 Insulin Receptor Signaling SOCS3,INPP5F,GAB1,SGK1,SOS1,AKT3,IRS2,JAK2
24 Leptin Signaling in Obesity SOCS3,GNAS,LEPR,AKT3,JAK2
25 IL-22 Signaling SOCS3,AKT3
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or crispr-mediated deletion of SOCS3 (Supplemental 
Figure 2). Changes in SOCS3 levels were only detectable 
in our cell line with super-physiological expression of 
SOCS3.
SOCS3 is transcriptionally regulated by 17-
DMAG and the p38 pathway
Given that SOCS3 is silenced by DNA methylation 
in other malignancies, we first determined if a similar 
mechanism was acting in CLL cells. Comparison of 
methylation profiles in the SOCS3 CpG island as well 
as further upstream regions (Supplemental Figure 3A) 
revealed no significant differences in CLL DNA 
methylation relative to normal B cells (Supplemental 
Figure 3B). Quantitative DNA methylation analysis of the 
SOCS3 CpG island using the MassARRAY MassCleave 
assay was performed on two additional regions in the CpG 
island, one spanning intron 1 and exon 2 just upstream 
of the translational start site of SOCS3 (SOCS3-ATG; 
31 CpGs analyzed) the other 5’ of the TSS (SOCS3-5’; 
15 CpGs analyzed). No difference in DNA methylation 
between CLL and normal B cells was found (Supplemental 
Figure 3C). This suggests that SOCS3 is transcriptionally 
silenced by a mechanism other than methylation. In order 
to determine whether SOCS3 was induced in response to 
17-DMAG rather than 17-DMAG providing enhanced 
transcript stability, we treated CLL cells with 17-DMAG 
for 16 hours followed by the addition of actinomycin 
D to inhibit new transcription. SOCS3 transcript 
decay was then monitored up to 4 hours. As expected, 
SOCS3 transcript is significantly induced by 17-DMAG 
Table 2: Ingenuity canonical pathways involving SOCS3: 17-DMAG vs Vehicle
# Ingenuity Canonical Pathways Involving SOCS3: 
DMAG vs Veh
Molecules
1 Type I Diabetes Mellitus Signaling SOCS3,HLA-DRB1,HLA-DMA, 
HLA-DRA,HLA-DMB,HLA-DQA1,CD86, 
HLA-DOB,HLA-DQB1,HSPD1
2 D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis SOCS3,PTPN6,PPP1R16B,PTPRO,DUSP10
3 D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis SOCS3,PTPN6,PPP1R16B,PTPRO,DUSP10
4 D-myo-inositol-5-phosphate Metabolism SOCS3,PTPN6,PPP1R16B,PTPRO,DUSP10
5 3-phosphoinositide Degradation SOCS3,PTPN6,PPP1R16B,PTPRO,DUSP10
6 3-phosphoinositide Biosynthesis SOCS3,PTPN6,PPP1R16B,PTPRO,DUSP10
7 Superpathway of Inositol Phosphate Compounds SOCS3,PTPN6,PPP1R16B,PTPRO,DUSP10
8 Role of JAK2 in Hormone-like Cytokine Signaling SOCS3,PTPN6
9 IL-6 Signaling VEGFA,SOCS3,HSPB1
10 Erythropoietin Signaling SOCS3,PTPN6
11 Growth Hormone Signaling SOCS3,PTPN6
12 Role of Macrophages, Fibroblasts and Endothelial Cells in 
Rheumatoid Arthritis
VEGFA,SOCS3,TLR10,TLR7,IGHG1
13 JAK/Stat Signaling SOCS3,PTPN6
14 STAT3 Pathway SOCS3,PTPN6
15 IL-22 Signaling SOCS3
16 Role of JAK family kinases in IL-6-type Cytokine Signaling SOCS3
17 IL-9 Signaling SOCS3
18 Role of JAK1 and JAK3 in γc Cytokine Signaling SOCS3
19 IL-10 Signaling SOCS3
20 Prolactin Signaling SOCS3
21 Leptin Signaling in Obesity SOCS3
22 IGF-1 Signaling SOCS3
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Figure 1: SOCS3 is silenced in CLL and re-expressed following treatment with 17-DMAG. A. Real time RT-PCR for 
SOCS3 in normal B cells compared to CLL B cells (N = 7 and N = 8, respectively). Fold change is shown relative to the CLL average 
expression. B. Real time RT-PCR for SOCS3 in CLL B cells treated with vehicle control, or 17-DMAG for 8, 16 and 24 hours (N = 19, 
N = 14 and N = 8, respectively), or in normal B cells treated with 17-DMAG for 24 hours (N = 5). Data are normalized to TBP transcript and 
represented as fold change in expression of 17-DMAG treated relative to the vehicle control. Circles represent individual patient samples 
and the bar represents the average of all patient samples. C. Fold change in SOCS3 expression following 17-DMAG treatment of CLL B 
cells (N = 24) for 16 hours (X-axis, 17-DMAG relative to Vehicle) is compared to 17-DMAG mediated cell killing determined by Ann/PI 
staining at 24 hours (Y-axis, percent difference in live cells in 17-DMAG relative to Vehicle).
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(Figure 2A, 17-DMAG ActD-0hr vs. Vehicle ActD-0hr, p 
<.001). However, in the presence of actinomycin D, there 
is no significant difference in SOCS3 transcript stability 
over 4 hours (Figure 2A, 17-DMAG ActD-4hr vs 17-
DMAG time ActD-0hr, p = 0.481). These results indicate 
a mechanism of transcriptional activation versus transcript 
stabilization.
In our microarray data, FosL2 and JunD were also 
significantly repressed in CLL cells compared to normal 
B cells, and were up-regulated following 17-DMAG 
treatment (Supplemental Tables 2 and 4). The p38 MAPK 
pathway directly regulates Fos family genes [19], and 
several studies have indicated that the p38 pathway can 
also regulate SOCS3 transcript [20–22]. Finally, several 
CLL therapies (flavopiridol, rituximab and OSU-DY7) 
have been shown to induce p38 dependent apoptosis 
in CLL [23–25]. Therefore we hypothesized that p38 
signaling was induced by 17-DMAG in CLL, and 
responsible for the increase in SOCS3 transcript and 
subsequent cell death. We treated primary CLL cells with 
17-DMAG for 16, 24 and 48 hours in the presence or 
absence of the p38/MAPK pathway inhibitor SB203580 
(both 2.5 and 10 uM). We found that 17-DMAG does 
in fact induce p38 activity, indicated by increased 
phosphorylation of p38 (Figure 2B). Furthermore, 
treatment with SB203580 at either dose significantly 
inhibited SOCS3 up-regulation following 17-DMAG 
treatment (Figure 2C; p = 0.024 for 2.5 uM SB, and p = 
0.002 for 10uM SB at 16 hours). Additionally, we found 
that treatment with SB203580 impaired the ability of the 
Hsp90 inhibitor to kill the CLL cells (Figure 2Dii; p = 
0.040 for 2.5 uM SB, and p = 0.015 for 10uM SB at 24 
hours, and Figure 2Diii; p = 0.018 for 2.5 uM SB, and 
p = 0.006 for 10uM SB at 48 hours). 17-DMAG had no 
cytotoxic effect on the cells at 16 hours (p = 0.142, Figure 
2Di) and the p38 inhibitor therefore showed no significant 
difference in 17-DMAG mediated killing, which is 
consistent with our previous data that Hsp90 inhibition 
does not initiate significant cell death prior to 24 hours.
Re-expression of SOCS3 inhibits IL-6 and SDF-1 
induced signaling and migration
SOCS3 can disrupt the SDF-1/CXCR4 pathway 
[26–28] as well as signaling to either focal adhesion kinase 
(FAK) or AKT which are both key survival factors induced 
by IL-6 in CLL. Therefore in order to determine the 
downstream effects of SOCS3 regulation in CLL cells, we 
analyzed the effect of IL-6 and SDF-1 stimulation. CLL 
cells were treated with 17-DMAG for 8 hours (the earliest 
time point of SOCS3 induction without any evidence of 
cell death), followed by stimulation with recombinant 
human IL-6 (rhIL-6). Phosphorylation of STAT3 (Tyr705) 
was induced following rhIL-6 stimulation, and this effect 
was substantially blocked with 17-DMAG pre-treatment 
(Figure 3A). This occurred prior to degradation of total 
STAT3 protein, which is ultimately expected due to loss of 
the chaperone function provided by Hsp90 [29]. When 17-
DMAG and IL-6 are added concurrently, p-STAT3 is still 
reduced, albeit less than pre-treatment with 17-DMAG 
(data not shown). This is again consistent with the time 
required for SOCS3 induction rather than an immediate 
direct effect of 17-DMAG on STAT3 phosphorylation. 
In a manner similar to IL-6, we found that an 8 hour 
pre-treatment with 17-DMAG is able to block the SDF-
1 induced phosphorylation of AKT as well (Figure 3B, 
induced p-AKT is the upper band indicated by the red 
arrow). Densitometry for p-AKT relative to total AKT 
(each protein first normalized to actin) is shown below the 
blots. Jurkat T cell lysate was used as a positive control 
as these cells have been shown to have high levels of 
constitutive p-AKT.
Given this effect on SDF-1 signaling, we next 
sought to determine whether this pathway was functionally 
inhibited following Hsp90 treatment using in vitro cell 
migration assays. Pre-treatment of primary CLL cells 
with 17-DMAG significantly inhibited the migration 
towards both SDF-1 (p = 0.006) and CXCL13 (p < 0.001) 
(Figure 4A). Interestingly, even though very few cells 
migrated towards the control media with no chemokine, 
17-DMAG still had a significant effect on migration (p < 
0.001) indicating that inhibition of Hsp90 plays a role in 
the overall motility of the CLL cells. Finally, under the 
same conditions we determined the effect of 17-DMAG 
on the migration of normal B cells. While these cells 
were able to efficiently migrate towards chemokine (even 
more than the CLL B cells), 17-DMAG was not able to 
significantly inhibit the migration of these cells towards 
SDF-1 (p = 0.556) or CXCL13 (p = 0.389) (Figure 4B), 
which is consistent with the real time data showing less 
induction of SOCS3 in normal B cells.
Exogenous expression of SOCS3 in a B cell line 
inhibits IL-6 and SDF-1 induced signaling
Finally, in order to verify the specific role of 
SOCS3 on these signaling pathways, we utilized a CLL 
B-cell line previously described by our lab (OSU-CLL) 
to over-express SOCS3. This cell line was chosen for 
mechanistic studies as it is the only line where SOCS3 
induction with 17-DMAG is evident, and unlike other 
CLL cell lines, OSU-CLL responds to IL-6 induction. As 
shown in Figure 5, exogenous over-expression of SOCS3 
is able to reduce the phosphorylation of STAT3 following 
stimulation with IL-6, whereas the control vector or 
SOCS3 expressed in the reverse orientation had no effect 
on this signaling. These data suggest that SOCS3 is able to 
regulate cell signaling in a CLL B-cell line.
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Figure 2: Activation of p38 following treatment with 17-DMAG induces SOCS3. A. CLL B cells (N = 5) were treated with 
vehicle control or 17-DMAG for 16 hours, followed by actinomycin D. RNA was collected at 0, 0.5, 1, 2 and 4 hours and SOCS3 transcript 
stability was measured by real time RT-PCR. B. Immunoblot analysis in representative CLL patient samples (N=4) for phospho-p38 
(indicating activation) following 17-DMAG treatment (1 uM) for 16 hours. C. Real-time RT-PCR for SOCS3 in CLL B cells treated with 
17-DMAG for 16 hours in the presence or absence of SB203580 (2.5 and 10 uM, N = 12). Data are normalized to TBP transcript and 
represented as fold change in expression of relative to the vehicle only control. D. Viability following 17-DMAG treatment for 16 (i), 24 
(ii) and 48 (iii) hours in the presence or absence of SB203580 (2.5 and 10 uM, N = 12) determined by Ann/PI staining and flow cytometry.
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DISCUSSION
The regulation of SOCS3 has not been implicated 
in CLL. In this study, we have provided evidence that 
SOCS3 can regulate important cell survival pathways in 
CLL. The correlation between up-regulation of SOCS3 
and cell death in primary CLL cells indicate that this is 
an important factor in the mechanism of Hsp90 inhibitor 
mediated cell death.
We have provided evidence that the regulation 
of SOCS3 in CLL is not due to silencing via DNA 
methylation, but rather our data does support a role for 
p38 signaling in SOCS3 transcriptional regulation. In 
general, p38 signaling is reported to induce cell survival 
in CLL cells, likely due to crosstalk with the tumor 
microenvironment [30]. However, some studies have 
shown that CD40L induced p38 is actually reduced in CLL 
cells compared to normal B cells [31], and our array data 
suggest that some of the downstream substrates of this 
pathway (Jun/Fos transcription factors) are also silenced in 
CLL. Therefore while p38 signaling may have dual roles 
in CLL, we have demonstrated here that it is involved in 
SOCS3 up-regulation and the cytotoxic mechanism of 17-
DMAG treatment.
SOCS3 is predominantly considered a negative 
regulator of the IL-6 induced JAK/STAT pathway which 
can be constitutively active in CLL due to interaction 
with other cells in the tumor microenvironment, or due 
to treatment related complications such as cytokine 
release following tumor lysis. In addition to IL-6, the 
T cell marker CD5, which is aberrantly expressed on 
CLL B-cells, has been shown to signal through STAT3 
to activate cytokine production in CLL [32]. Another 
signaling pathway regulated by SOCS3 and particularly 
important to the migration and survival of CLL cells is 
the SDF-1/CXCR4 pathway. SDF-1 signaling in B cells 
has been shown to induce phosphorylation of BTK and 
downstream PLCγ2, which is in turn responsible for B 
Figure 3: 17-DMAG inhibits IL-6 and SDF-1 induced signaling. A. CLL B cells were treated with vehicle control or 17-DMAG 
for 8 hours, followed by stimulation with recombinant human IL-6 (rhIL-6). Immunoblots were performed for p-STAT3 and total STAT3, 
as well as a loading control actin. Results shown are representative of 12 patient samples. B. CLL B cells were treated with vehicle control 
or 17-DMAG for 8 hours, followed by stimulation with recombinant human SDF-1 (rhSDF-1). Immunoblots were performed for p-AKT 
and total AKT, as well as a loading control Actin. Densitometry for p-AKT (indicated by the red arrow) relative to total AKT (each protein 
first normalized to actin) is indicated below the blots. Results shown are representative of 6 patient samples.
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Figure 4: 17-DMAG and re-expression of SOCS3 inhibits migration. A. CLL B cells (N = 14 for CXCL13, N = 16 for SDF-1) 
were re-suspended at 5 x 106 cells/mL and treated with vehicle control or 17-DMAG for 5 hours, then were placed in the upper well of 
24-well transwell plates. The bottom wells contained either media alone, or media with recombinant SDF-1 (200 ng/mL) or CXCL13 
(1000 ng/mL). Cells in the lower chamber were collected after 3 additional hours (for a total of 8 hours 17-DMAG treatment), and percent 
migration is calculated relative to the input. B. Normal B cells (N = 4) were re-suspended at 5 x 106 cells/mL and treated with vehicle control 
or 17-DMAG for 5 hours, then were placed in the upper well of 24-well transwell plates. The bottom wells contained either media alone, or 
media with recombinant SDF-1 (200 ng/mL) or CXCL13 (1000 ng/mL). Cells in the lower chamber were collected after 3 additional hours 
(for a total of 8 hours 17-DMAG treatment), and percent migration is calculated relative to the input.
Figure 5: Re-expression of SOCS3 inhibits IL-6 signaling in a CLL cell line. The OSU-CLL B cell line was modified to over-
express the SOCS3 coding sequence. Cell lines expressing the coding sequence in the reverse orientation or the empty vector only were 
used as controls. Immunoblots were performed for p-STAT3, total STAT3, and SOCS3, as well as a loading control Actin.
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cell migration [33]. Phosphoproteomic analysis identified 
several other targets downstream of SDF-1 signaling 
associated with CLL cell survival, including Hsp90 
[34]. Finally, drugs such as the tyrosine kinase inhibitor 
dasatinib have been shown to inhibit CLL cell migration 
and signaling to AKT by blocking SDF-1 signaling [35].
Given the documented importance of these signaling 
pathways in the survival of CLL cells, the ability to 
therapeutically target these pathways simultaneously 
would be advantageous in the treatment of CLL. Similar 
to what has been demonstrated in other cell types, our data 
show that 17-DMAG impaired both the phosphorylation 
of STAT3 following IL-6 stimulation as well as AKT 
phosphorylation following SDF-1 stimulation. 17-DMAG 
also reduced the ability of CLL cells to migrate in vitro 
towards chemokine. Consistent with what has been 
previously reported, the normal B cells migrated more 
than CLL both towards media alone or media containing 
chemokine [34]. However, 17-DMAG did not up-regulate 
SOCS3 in normal B cells to the same extent as CLL B 
cells (Figure 1C), and also did not inhibit the migration 
of normal B cells (Figure 4B). These results highlight 
the importance of this up-regulation as a tumor-specific 
mechanism.
In conclusion, we have demonstrated that up-
regulation of SOCS3 via the p38 pathway is involved 
in the mechanism of Hsp90 inhibitor induced CLL cell 
death. Higher SOCS3 levels have been shown to be 
associated with the lack of bulky lymphadenopathy and 
splenomegaly in CLL [36]. However, this work provides 
the first evidence of the mechanism of SOCS3 regulation 
in CLL, and uncovers a potentially new therapeutic 
target in this disease. We have demonstrated this using 
the Hsp90 inhibitor 17-DMAG, however the role of 
SOCS3 independent of Hsp90 inhibitors should also be 
explored. This could include a screen for other inhibitors 
that more specifically regulate SOCS3, or potentially the 
development of a small molecule SOCS3 mimetic. Due 
to the documented role of SOCS3 silencing in other types 
of cancer, this type of therapeutic intervention could be 
applicable to the treatment of acute leukemia and solid 
tumors as well.
MATERIALS AND METHODS
Patients, cell separation, culture conditions, 
and reagents
For in vitro studies, written, informed consent was 
obtained to procure cells from patients with previously 
diagnosed CLL as defined by the modified NCI criteria 
[37]. Mononuclear cells from CLL patients and normal 
volunteers were isolated and placed in culture as 
previously described by our group [9]. Cells were 
grown in RPMI media with 10% fetal bovine serum, 
l-glutamine and antibiotics. No other additives were 
included with the exception of cell migration experiments 
where recombinant SDF-1 and CXCL13 were added to 
the media. 17-DMAG was obtained from the Division 
of Cancer Treatment and Diagnosis, National Cancer 
Institute (Bethesda, MD).
Microarray analysis
Gene expression were analyzed by Affymetrix 
Expression Console software. RMA method was used to 
do background correction, normalization and probe set 
summarization. A filtering method based on percentage 
of arrays above noise cutoff was applied to filter out low 
expression genes. Microarray results are available through 
GEO entry #GSE76546.
Viability assays
Apoptosis was determined by staining with annexin 
V-FITC and propidium iodide (PI). After exposure to 1 
uM 17-DMAG, cells were stained in 1X binding buffer 
(BD Biosciences, San Jose, CA). Cell death was assessed 
by flow cytometry using a Beckman-Coulter cytometer 
(Beckman-Coulter, Miami, FL). Ten thousand cells were 
counted for each sample, and data was analyzed with the 
Kaluza software package (Beckman-Coulter).
Cell migration assays
Cells were pretreated with 1 uM 17-DMAG for 5 
hours. Cells (5x106 cells/mL) were then transferred to the 
upper chamber of a 24-transwell plate with a 5μm filter. 
Chambers were placed into wells containing media with 
either no chemokine (control), recombinant human SDF-
1 (200 ug/mL) or CXCL13 (1000 ng/mL). Migration was 
permitted for 3 hours, and cells in the lower chamber were 
collected and counted for 20 seconds on high speed on a 
Beckman Coulter FC500 flow cytometer. A 1/20 dilution 
of input cells was also determined (input).
Immunoblot analysis
Antibodies used for immunoblots included AKT, 
p-AKT, STAT3, p-STAT3, p38 and p-p38 (Cell Signaling, 
Danvers, MA); SOCS3 (Abcam, Cambridge, MA; Cell 
Signaling and Santa Cruz Biotechnology, Santa Cruz, 
CA); and actin (Santa Cruz). Protein (50 μg/lane) was 
separated on polyacrylamide gels and transferred onto 
nitrocellulose. Following antibody incubations, proteins 
were detected with chemiluminescent substrate (Pierce) 
and quantified using a ChemiDoc system with Quantity 
One software (Bio-Rad Laboratories, Hercules, CA).
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Real-time RT-PCR
RNA was extracted by phenol chloroform isolation 
using TRIzol reagent (Invitrogen, Grand Island, NY) 
and purified using Qiagen RNeasy columns (Qiagen, 
Valencia, CA). cDNA was prepared with SuperScript 
First-Strand Synthesis System for RT-PCR (Invitrogen). 
Real-time polymerase chain reaction was performed using 
commercially available primers (Applied Biosystems, 
Foster City, CA). Detection was performed using an 
ABI Prism 7700 sequence detection system (Applied 
Biosystems). Average relative expression (treatment 
compared to media) was normalized to the internal control 
genes TBP or 18S.
Statistical analysis
Linear mixed effects models were used to assess 
differences between conditions of interest for experiments 
involving RT-PCR data (ΔCT values; Figure 1A, 1B, and 
2B), viability (% Ann/PI negative cells; Figure 2C), and 
migration (% of input, log- transformed; Figure 4). For 
Figure 1C, the Pearson correlation was calculated to assess 
the linear relationship between the % change in viability 
and SOCS3 fold change (log2-transformed values). All 
analyses were performed using SAS/STAT software 
version 9.3 (SAS Institute, Inc., Cary, NC).
CONFLICT OF INTEREST
The authors have no conflicts to disclose related to 
this work.
GRANT SUPPORT
This work was supported by the National Cancer 
Institute (R35 CA197734-01, P01 CA81534, and K12 
CA133250), Sullivan Foundation, The Leukemia and 
Lymphoma Society (special scholar grant to EH) and The 
D. Warren Brown Foundation.
REFERENCES
1. Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, 
Jin VX, Sherman MH, Liu SJ, Dawson DW, Williams 
KE, Lanasa M, Liyanarachchi S, Lin TS, Marcucci G, 
Pekarsky Y, Davuluri R, et al. Epigenetic changes during 
disease progression in a murine model of human chronic 
lymphocytic leukemia. Proc Natl Acad Sci U S A. 2009; 
106:13433-13438.
2. Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi 
R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn 
J, Plass C, Marcucci G, Chan KK, Grever MR, Byrd 
JC. Phase I trial of low dose decitabine targeting DNA 
hypermethylation in patients with chronic lymphocytic 
leukaemia and non-Hodgkin lymphoma: dose-
limiting myelosuppression without evidence of DNA 
hypomethylation. Br J Haematol. 2010; 150:189-195.
3. Hertlein E, Byrd JC. Signalling to drug resistance in CLL. 
Best Pract Res Clin Haematol. 23:121-131.
4. Lopez-Guerra M, Colomer D. NF-kappaB as a therapeutic 
target in chronic lymphocytic leukemia. Expert Opin Ther 
Targets. 2010; 14:275-288.
5. Ashburner BP, Westerheide SD, Baldwin AS, Jr. The p65 
(RelA) subunit of NF-kappaB interacts with the histone 
deacetylase (HDAC) corepressors HDAC1 and HDAC2 to 
negatively regulate gene expression. Mol Cell Biol. 2001; 
21:7065-7077.
6. Elsharkawy AM, Oakley F, Lin F, Packham G, Mann 
DA, Mann J. The NF-kappaB p50:p50:HDAC-1 repressor 
complex orchestrates transcriptional inhibition of multiple 
pro-inflammatory genes. J Hepatol. 2010; 53:519-527.
7. Tong X, Yin L, Washington R, Rosenberg DW, Giardina 
C. The p50-p50 NF-kappaB complex as a stimulus-specific 
repressor of gene activation. Mol Cell Biochem. 2004; 
265:171-183.
8. Dong J, Jimi E, Zhong H, Hayden MS, Ghosh S. Repression 
of gene expression by unphosphorylated NF-kappaB 
p65 through epigenetic mechanisms. Genes Dev. 2008; 
22:1159-1173.
9. Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks 
KJ, Towns WH, 3rd, Goettl VM, Zhang X, Jarjoura D, 
Raymond CA, West DA, Croce CM, Byrd JC, Johnson 
AJ. 17-DMAG targets the nuclear factor-kappaB family 
of proteins to induce apoptosis in chronic lymphocytic 
leukemia: clinical implications of HSP90 inhibition. Blood. 
2010; 116:45-53.
10. Best OG, Che Y, Singh N, Forsyth C, Christopherson RI, 
Mulligan SP. The Hsp90 inhibitor SNX-7081 synergizes 
with and restores sensitivity to fludarabine in chronic 
lymphocytic leukemia cells with lesions in the TP53 
pathway: a potential treatment strategy for fludarabine 
refractory disease. Leuk Lymphoma. 2012; 53:1367-1375.
11. Best OG, Mulligan SP. Heat shock protein-90 inhibitor, 
NVP-AUY922, is effective in combination with 
fludarabine against chronic lymphocytic leukemia cells 
cultured on CD40L-stromal layer and inhibits their 
activated/proliferative phenotype. Leuk Lymphoma. 2012; 
53:2314-2320.
12. Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas 
DM, Guster SK, Grever MR, Lin TS, Byrd JC. Rituximab 
and 17-allylamino-17-demethoxygeldanamycin induce 
synergistic apoptosis in B-cell chronic lymphocytic 
leukaemia. Br J Haematol. 2007; 139:837-844.
13. Walsby E, Pearce L, Burnett AK, Fegan C, Pepper C. The 
Hsp90 inhibitor NVP-AUY922-AG inhibits NF-kappaB 
signaling, overcomes microenvironmental cytoprotection and 
is highly synergistic with fludarabine in primary CLL cells. 
Oncotarget. 2012; 3:525-534. doi: 10.18632/oncotarget.491.
Oncotarget28695www.impactjournals.com/oncotarget
14. Capello D, Deambrogi C, Rossi D, Lischetti T, Piranda D, 
Cerri M, Spina V, Rasi S, Gaidano G, Lunghi M. Epigenetic 
inactivation of suppressors of cytokine signalling in 
Philadelphia-negative chronic myeloproliferative disorders. 
Br J Haematol. 2008; 141:504-511.
15. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello 
JF, McCormick F, Jablons DM. SOCS-3 is frequently 
silenced by hypermethylation and suppresses cell growth 
in human lung cancer. Proc Natl Acad Sci U S A. 2003; 
100:14133-14138.
16. Sutherland KD, Lindeman GJ, Choong DY, Wittlin 
S, Brentzell L, Phillips W, Campbell IG, Visvader JE. 
Differential hypermethylation of SOCS genes in ovarian 
and breast carcinomas. Oncogene. 2004; 23:7726-7733.
17. Tokita T, Maesawa C, Kimura T, Kotani K, Takahashi K, 
Akasaka T, Masuda T. Methylation status of the SOCS3 
gene in human malignant melanomas. Int J Oncol. 2007; 
30:689-694.
18. Hertlein E, Beckwith KA, Lozanski G, Chen TL, Towns 
WH, Johnson AJ, Lehman A, Ruppert AS, Bolon B, 
Andritsos L, Lozanski A, Rassenti L, Zhao W, Jarvinen 
TM, Senter L, Croce CM, et al. Characterization of a New 
Chronic Lymphocytic Leukemia Cell Line for Mechanistic 
and Studies Relevant to Disease. PLoS One. 2013; 
8:e76607.
19. Hazzalin CA, Cuenda A, Cano E, Cohen P, Mahadevan 
LC. Effects of the inhibition of p38/RK MAP kinase on 
induction of five fos and jun genes by diverse stimuli. 
Oncogene. 1997; 15:2321-2331.
20. Barclay JL, Anderson ST, Waters MJ, Curlewis JD. 
Characterization of the SOCS3 promoter response to 
prostaglandin E2 in T47D cells. Mol Endocrinol. 2007; 
21:2516-2528.
21. Canfield S, Lee Y, Schroder A, Rothman P. Cutting edge: 
IL-4 induces suppressor of cytokine signaling-3 expression 
in B cells by a mechanism dependent on activation of p38 
MAPK. J Immunol. 2005; 174:2494-2498.
22. Chaves de Souza JA, Nogueira AV, Chaves de Souza PP, 
Kim YJ, Silva Lobo C, Pimentel Lopes de Oliveira GJ, 
Cirelli JA, Garlet GP, Rossa C, Jr. SOCS3 expression 
correlates with severity of inflammation, expression of 
proinflammatory cytokines, and activation of STAT3 and 
p38 MAPK in LPS-induced inflammation in vivo. Mediators 
Inflamm. 2013; 2013:650812.
23. Bai LY, Ma Y, Kulp SK, Wang SH, Chiu CF, Frissora F, 
Mani R, Mo X, Jarjoura D, Byrd JC, Chen CS, Muthusamy 
N. OSU-DY7, a novel D-tyrosinol derivative, mediates 
cytotoxicity in chronic lymphocytic leukaemia and Burkitt 
lymphoma through p38 mitogen-activated protein kinase 
pathway. Br J Haematol. 2011; 153:623-633.
24. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander 
J. The chimeric anti-CD20 antibody rituximab induces 
apoptosis in B-cell chronic lymphocytic leukemia cells 
through a p38 mitogen activated protein-kinase-dependent 
mechanism. Blood. 2002; 99:1314-1319.
25. Pepper C, Thomas A, Fegan C, Hoy T, Bentley P. 
Flavopiridol induces apoptosis in B-cell chronic 
lymphocytic leukaemia cells through a p38 and ERK MAP 
kinase-dependent mechanism. Leuk Lymphoma. 2003; 
44:337-342.
26. Le Y, Zhu BM, Harley B, Park SY, Kobayashi T, Manis JP, 
Luo HR, Yoshimura A, Hennighausen L, Silberstein LE. 
SOCS3 protein developmentally regulates the chemokine 
receptor CXCR4-FAK signaling pathway during B 
lymphopoiesis. Immunity. 2007; 27:811-823.
27. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara 
K, Kitagawa T, Yamamoto J, Kubo T, Yoshikawa H. 
Methylation silencing of SOCS-3 promotes cell growth and 
migration by enhancing JAK/STAT and FAK signalings 
in human hepatocellular carcinoma. Oncogene. 2005; 
24:6406-6417.
28. Pello OM, Moreno-Ortiz Mdel C, Rodriguez-Frade JM, 
Martinez-Munoz L, Lucas D, Gomez L, Lucas P, Samper 
E, Aracil M, Martinez C, Bernad A, Mellado M. SOCS 
up-regulation mobilizes autologous stem cells through 
CXCR4 blockade. Blood. 2006; 108:3928-3937.
29. Prinsloo E, Kramer AH, Edkins AL, Blatch GL. STAT3 
interacts directly with Hsp90. IUBMB Life. 2012; 
64:266-273.
30. Ringshausen I, Dechow T, Schneller F, Weick K, Oelsner 
M, Peschel C, Decker T. Constitutive activation of the 
MAPkinase p38 is critical for MMP-9 production and 
survival of B-CLL cells on bone marrow stromal cells. 
Leukemia. 2004; 18:1964-1970.
31. Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, 
Tierens AM, Myklebust JH, Kolstad A. Phospho-specific 
flow cytometry identifies aberrant signaling in indolent 
B-cell lymphoma. BMC Cancer. 2012; 12:478.
32. Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers 
JO, Berthou C, Mageed RA, Renaudineau Y, Youinou P. 
CD5 promotes IL-10 production in chronic lymphocytic 
leukemia B cells through STAT3 and NFAT2 activation. J 
Immunol. 2011; 186:4835-4844.
33. de Gorter DJ, Beuling EA, Kersseboom R, Middendorp 
S, van Gils JM, Hendriks RW, Pals ST, Spaargaren M. 
Bruton's tyrosine kinase and phospholipase Cgamma2 
mediate chemokine-controlled B cell migration and homing. 
Immunity. 2007; 26:93-104.
34. O'Hayre M, Salanga CL, Kipps TJ, Messmer D, Dorrestein 
PC, Handel TM. Elucidating the CXCL12/CXCR4 
signaling network in chronic lymphocytic leukemia through 
phosphoproteomics analysis. PLoS One. 2010; 5:e11716.
35. McCaig AM, Cosimo E, Leach MT, Michie AM. Dasatinib 
inhibits CXCR4 signaling in chronic lymphocytic 
leukaemia cells and impairs migration towards CXCL12. 
PLoS One. 2012; 7:e48929.
Oncotarget28696www.impactjournals.com/oncotarget
36. Levidou G, Sachanas S, Pangalis GA, Kalpadakis C, 
Yiakoumis X, Moschogiannis M, Sepsa A, Lakiotaki 
E, Milionis V, Kyrtsonis MC, Vassilakopoulos TP, 
Tsirkinidis P, Kontopidou F, Kokoris S, Siakantaris M, 
Angelopoulou M, et al. Immunohistochemical analysis 
of IL-6, IL-8/CXCR2 axis, Tyr p-STAT-3, and SOCS-3 
in lymph nodes from patients with chronic lymphocytic 
leukemia: correlation between microvascular characteristics 
and prognostic significance. Biomed Res Int. 2014; 
2014:251479.
37. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, 
O'Brien S, Rai KR. National Cancer Institute-sponsored 
Working Group guidelines for chronic lymphocytic 
leukemia: revised guidelines for diagnosis and treatment. 
Blood. 1996; 87:4990-4997.
